Intensive systemic chemotherapy is effective against recurrent malignant Brenner tumor of the ovary: An analysis of 10 cases within a single center  by Han, Ji-Hyun et al.
lable at ScienceDirect
Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 178e182Contents lists avaiTaiwanese Journal of Obstetrics & Gynecology
journal homepage: www.t jog-onl ine.comOriginal ArticleIntensive systemic chemotherapy is effective against recurrent
malignant Brenner tumor of the ovary: An analysis of 10 cases within
a single center
Ji-Hyun Han, Dae-Yeon Kim*, Shin-Wha Lee, Jeong-Yeol Park, Jong-Hyeok Kim,
Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Koreaa r t i c l e i n f o
Article history:
Accepted 5 March 2014
Keywords:
Brenner tumor
chemotherapy
malignancy
ovary* Corresponding author. Department of Obstetrics a
Ulsan College of Medicine, Asan Medical Center, 88, O
Seoul 138-736, South Korea.
E-mail address: kdyog@amc.seoul.kr (D.-Y. Kim).
http://dx.doi.org/10.1016/j.tjog.2014.03.008
1028-4559/Copyright © 2015, Taiwan Association of Oa b s t r a c t
Objective: Malignant Brenner tumors (MBTs) of the ovary are very rare, and their deﬁnition, biology, and
treatment modality have not been established. This study investigated the clinical characteristics of MBTs
and the importance of chemotherapy for recurrent disease.
Materials and methods: We conducted a retrospective analysis of 10 patients with MBT of the ovary
treated at a single tertiary center from 1991 to 2013.
Results: The median age was 55.5 years (range, 37e68 years). Nine of the 10 patients were symptomatic.
The median size of the ovarian tumors was 10.5 cm (range, 2.5e25.0 cm). The cancer antigen-125 level
was elevated in three patients. Six patients had a stage I tumor, one had a stage II tumor, two had a stage
III tumor, and one had a stage IV tumor. Six patients received systemic adjuvant chemotherapy after
surgery. The mean follow-up duration was 54.5 months (range, 8e173 months). Disease recurrence
occurred in four of the 10 patients. The median time to recurrence was 11 months (range, 9e18 months).
Two patients with locoregional recurrence showed favorable results after chemotherapy, regardless of
the initial stage of the tumor. The patient with the stage IIIC tumor is alive at 13 months after recurrence
on current chemotherapy. The patient with the stage IV tumor showed no evidence of the disease > 12
years after the last chemotherapy. Lastly, two patients with distant recurrence died after showing a long-
term survival of 49 months and 88 months, respectively, after recurrence and intensive chemotherapy.
Conclusion: Our results showed that systemic chemotherapy is beneﬁcial in patients with recurrence of a
primary MBT of the ovary, especially in the locoregional recurrence.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Brenner tumors are rare epithelial tumors of the ovary that
comprise 1.5% of all ovarian tumors [1]. Although initially thought
to be benign, there have been several reports in the past few de-
cades reporting approximately 1% of Brenner tumors to be malig-
nant [2]. The conventional treatment modality is surgical resection;
however, only a little information is available on the deﬁnition,
biology, optimal treatment, and prognosis of malignant Brennernd Gynecology, University of
lympic-ro, 43-gil, Songpa-gu,
bstetrics & Gynecology. Publishedtumors (MBTs). Furthermore, the precise regimen and beneﬁt of
systemic chemotherapy remain unknown. In this study, we report
10 cases with MBT of the ovary, analyze its clinical, demographic,
and histological features, and discuss the importance of chemo-
therapy for recurrent disease.
Materials and methods
We conducted a retrospective review of 10 patients with MBT of
the ovary who were treated at the Gynecology Department of the
Asan Medical Center in Seoul, Korea over a 22-year period from
May 1991 to September 2013. Informed consent was obtained from
each patient. The 1988 International Federation of Gynecology and
Obstetrics staging system was used to classify each patient into an
appropriate stage. Histopathological analyses were performed byby Elsevier Taiwan LLC. All rights reserved.
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to the criteria described by Hull and Campbell [3]. All ﬁndings were
conﬁrmed by a second pathologist. Medical records were reviewed,
and demographics, clinical ﬁndings (diagnosis and treatment data),
and current disease status were obtained. Numeric data were
subjected to descriptive statistics using SPSS software (version 21.0;
SPSS Inc., Chicago, IL, USA).Results
There were 10 cases of MBT out of 92 cases of ovarian Brenner
tumor diagnosed over a 22-year period by a pathologist and
conﬁrmed by a second pathologist (Fig. 1). The age of the patients
ranged from 37 years to 68 years, with a median age of 55.5 years.
The mean parity was 2.5 (range, 2e5). Six of the 10 patients were
postmenopausal. Most patients (n ¼ 7; 70%) presented with either
abdominal pain or discomfort. The remaining three patients pre-
sented with either a pelvic mass or vaginal bleeding, while one out
of three was asymptomatic (Table 1). The level of preoperative
cancer antigen-125 (CA-125) was elevated in three patients (cutoff
level, 35 IU/mL). Ascites was detected in four patients by a preop-
erative radiologic examination or an intraoperative observation. All
patients underwent preoperative computed tomography (CT). Fig. 2
shows three CT scans from a representative patient. The median
size of the ovarian tumors was 10.5 cm (range, 2.5e25.0 cm) in
maximal diameter. Seven patients had a tumor in the right ovary,
and one patient had tumors in both ovaries. Six patients had a stage
I tumor, one had a stage II tumor, two had a stage III tumor, and one
had a stage IV tumor. Six patients received postoperative systemic
chemotherapy. The regimens consisted of platinum-based taxol.
Taxol was administered at a dose of 175 mg/m2. The carboplatin
dose was calculated from the area under the concentration time
curve 4e6 for low dose, and the cisplatin dose was 75 mg/m2. The
change in tumor burden was assessed according to the World
Health Organization criteria published in 1981. All six patients who
underwent postoperative chemotherapy achieved complete
response. The mean follow-up duration was 54.5 months (range,
8e173 months). Disease recurrence occurred in four of the 10 pa-
tients, and the mean time to recurrence was 11 months (range,
9e18 months). Two patients with distantly recurrent disease diedFig. 1. Brenner tumors of the ovary. (A) This benign Brenner tumor shows solid and cystic
abundant dense ﬁbroblastic stromal tissue. (B) This malignant Brenner tumor shows a
component (left side). (Hematoxylineeosin; original magniﬁcation, 40).even though they received intensive chemotherapy. The ﬁrst pa-
tient lived for 44 months after metastasis to the liver and bone. The
second patient lived for 3 months after metastasis to the lung and
left supraclavicular lymph nodes. One patient with initial metas-
tasis to the left supraclavicular lymph node is currently receiving
chemotherapy after locoregional recurrence and the other has no
evidence of the disease > 12 years after the last chemotherapy.
These results are summarized in Table 2.Discussion
Brenner tumors are rare ovarian tumors, ﬁrst described by
McNaughton-Jones in 1898 and then named by Frits Brenner in
1907. They are epithelial neoplasms possibly of müllerian origin
and usually benign, although there is a wide spectrum between
benign andmalignant conditions, which are rarely detected [4]. The
ﬁrst case of MBT was published by Von Numers in 1945, but only a
few reports on MBTs of the ovary are published to date, and their
deﬁnition, biology, and treatment modality have not been estab-
lished yet [5]. In this study, we presented 10 cases with MBT of the
ovary and analyzed its clinical, demographic, and histological fea-
tures, and survival outcomes.
All histopathological diagnoses were performed according to
the criteria described by Hull and Campbell [3], which com-
plemented Idelson's [6] criteria as follows: (1) presence of malig-
nant histological features; (2) presence of an intimate association
between malignant and benign components or a borderline Bren-
ner tumor (in the absence of a benign or borderline Brenner
component, the tumor should be classiﬁed as a transitional cell
carcinoma [7]); (3) absence of mucinous cystadenomas or separa-
tion of the mucinous cystadenomas from both the benign tumor
and the MBT; and (4) demonstration of stromal invasion by
epithelial elements of the MBT.
In an earlier study of 48 cases including three malignant cases,
the mean age of patients was 60 years, and most were post-
menopausal women with abdominal symptoms and a unilateral
abdominopelvic mass [8]. The median age of our patients was 55.5
years (range, 37e68 years), similar to the study by Ryback et al [8].
Six of the 10 patients were postmenopausal, and seven patients
presented with abdominal pain. Fox et al [9] presented cases withnests of bland epithelial cells that resemble a transitional epithelium surrounded by
cytologically malignant component with stromal invasion (right side) and a benign
Table 1
Clinical features, treatment, and outcome in 10 patients.
Patient
No.
Age (y) Menopause Parity FIGO
stage
Symptom Tumor site
(ovary)
Tumor
size (cm)
Ascites CA-125
(IU/mL)
Metastasis Operation Chemotherapy Recurrence
site
Time to
recurrence
(mo)
Follow-up
duration
(mo)
Current
status
1 37 d 2 IA Abdominal pain,
vaginal bleeding a
Right 8.0 d 35.5 d Incomplete b d d d 26 FUL
2 42 d 2 IA Vaginal bleeding c Left 3.0 d 21.1 d Complete d d d 155 FUL
3 59 þ 3 IV Abdominal pain Right 2.5 þ 10.7 Left SCLN Complete TP#5, d TC#6, HP#6 Pelvic cavity 9 173 NED
4 52 þ 3 IIIC Abdominal pain Right 10.5 þ 8.3 Peritoneal
seeding, PLN
Complete TC#9, HC#1, CC#2, GTC#6 Liver, bladder,
and bone
18 77 DOD
5 61 þ 2 IC Abdominal pain Right 13.5 þ 23.4 d Complete TC#6 d d 21 Died e
6 43 d 3 IIC Abdominal pain Bilateral 7.5/6.5
(right/left)
þ 724.0 d Complete TC#6, Ca#6, G#3, T#6,
Beva#10, VP16, RTx, A#3,
VP16, Beva#6
Left SCL, lung 9 101 DOD
7 59 þ 5 IA Abdominal pain,
Mass
Right 25.0 d 13.0 d Complete d d d 102 NED
8 68 þ 4 IA Abdominal pain,
mass
Right 12.5 d 38.5 d Incomplete f TC#6 d d 8 FUL
9 48 d 2 IIIC Asymptomatic Right 5.5 d 4.0 Peritoneal
seeding
Complete TC#6, TC#6, DP#1 Pelvic cavity 13 32 AWD
10 61 þ 2 IA Mass g Left 12.0 d 10.7 d Complete d d d 16 NED
A ¼ Adriamycin; AWD ¼ associated with disease; Beva ¼ bevacizumab; CA-125 ¼ cancer antigen-125; Ca ¼ camptobell; CC ¼ camptobellecarboplatin; DOD ¼ died of disease; DP ¼ docetaxelecisplatin; FIGO ¼ International
Federation of Gynecology and Obstetrics; FUL ¼ follow-up loss; G ¼ gemcitabine; GTC ¼ gemcitabineetaxolecarboplatin; HC ¼ hycamtinecarboplatin; HP ¼ hycamtinecisplatin; NED ¼ no evidence of disease; PLN ¼ pelvic
lymph node; RTx ¼ radiotherapy; SCLN ¼ supraclavicular lymph node; T ¼ taxol; TC ¼ taxolecarboplatin; TP ¼ taxolecisplatin; VP16 ¼ oral etoposide.
a Endometrial pathology results showed decidual changes with gestational hyperplasia.
b We preserved left adnexa because the patient was 37 years old.
c Endometrial pathology results showed a secretory phase.
d After neoadjuvant chemotherapy of TC#5, the operation was performed.
e The patient died of underlying autoimmune liver cirrhosis, not MBT.
f We did not perform the staging operation after previous left salpingo-oophorectomy, which was performed in another hospital, because the stage was presumed as IA according to the imaging study. Instead, the patient
received adjuvant chemotherapy.
g Endometrial pathology results showed a secretory phase.
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Fig. 2. Malignant Brenner tumor of the ovary in a 61-year-old woman. Contrast-
enhanced computed tomography shows a multiseptated cystic mass with solid com-
ponents. The solid components contain an area of dense calciﬁcation (arrow, A). (A)
Axial, (B) coronal, and (C) sagittal planes are shown.
Table 2
Summary of results.
No. of patients %
Age (y) 55.5 (range, 37e68)
Parity 2.5 (range, 2e5)
Menopause
Yes 6 60
No 4 40
Symptom a
Abdominal pain 7 70
Pelvic mass 3 30
Vaginal bleeding 2 20
Asymptomatic 1 10
CA-125 (IU/mL)
Normal 7 70
Increased 3 30
Ascites
Yes 4 40
No 6 60
Size of tumor (cm) 10.5 (range, 2.5e25.0)
Right 7 70
Left 2 20
Bilateral 1 10
FIGO stage
IA 5 50
IC 1 10
IIC 1 10
IIIC 2 20
IV 1 10
Chemotherapy
Yes 6 60
No 4 40
Recurrence
Yes 4 40
Locoregional 2
Distant 2
No 6 60
Time to recurrence (mo) 11.0 (range, 9e18)
Follow-up duration (mo) 54.5 (range, 8e173)
Current status
No evidence of disease 3
Associated with disease 1
Died of the disease 2
Died of another disease b 1
Follow-up loss 3
CA-125 ¼ cancer antigen-125; FIGO ¼ International Federation of Gynecology and
Obstetrics; MBT ¼ malignant Brenner tumor.
a Three patients presented more than one symptom.
b One patient died of underlying autoimmune liver cirrhosis, not MBT.
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vaginal bleeding and mild degrees of endometrial hyperplasia.
Eight of our patients underwent endometrial investigation peri-
operatively, but only two patients were admitted to our center for
abnormal vaginal bleeding and irregular menstruation. Endome-
trial biopsies of these two patients showed decidual changes with
gestational hyperplasia and secretory-phase endometrium,
respectively. One patient without vaginal bleeding showed simple
hyperplasia without atypia.
Peritoneal effusion is a rare event in MBT cases, occurring in
approximately 10% of patients [10]. In our study, ascites was
detected in four of the 10 cases by preoperative radiologic or
intraoperative ﬁndings, which is signiﬁcantly higher than that re-
ported by Driss et al [10]. However, all cytological ﬁndings were
normal. Although MBTs are typically unilateral, bilateral MBTs that
are heterogeneously solid and multilocular cystic can occur [11].
These ﬁndings are in agreement with our study, which showed
seven of the 10 MBTs of the ovary to consist of a mixture of solid
and cystic tissue. Furthermore, one patient had bilateral tumors of
the ovary.
Malignant tumor markers can monitor the effectiveness of
therapy and detect recurrence, but tumormarkers of MBTs have not
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tumor marker, was elevated in three patients, but there was no
correlation between malignancy and tumor burden or stage.
Ben Aissia et al [12] reported thatmetastasis occurs in half of the
cases and are mostly locoregional. The authors studied the partic-
ularities and coverage of Brenner tumor on the basis of a personal
report and of 160 cases listed in the literature. In our study,
locoregional metastasis was detected in the pelvic cavity of two
patients, and distant metastasis was detected in the left supra-
clavicular lymph nodes of one patient at the time of diagnosis. In
two of the four recurrent cases, two patients had locoregional
metastasis in the pelvic cavity and the other two patients had
distant metastasis in the liver and bone or left supraclavicular
lymph nodes and lung, respectively.
Basically, surgery is a cornerstone of therapy for women with
MBT as in other epithelial ovarian malignancies including total
abdominal hysterectomy, bilateral salpingo-oophorectomy, omen-
tectomy, appendectomy, and a systemic pelvic and paraaortic
lymph node dissection [13]. There is one report on the retroperi-
toneal metastatic spread of MBT, which was initially limited to the
unilateral ovary without regional or distant metastasis [14]. Thus, a
biopsy of pelvic lymph nodes should be recommended, even if the
tumor is localized only to the unilateral ovary without metastasis.
Unilateral oophorectomy is the procedure of choice only for benign
Brenner tumors in patients who desire ovarian conservation [15]. In
our study, most patients were either perimenopausal or post-
menopausal, and the remaining patients did not wish to preserve
their fertility. Eight patients underwent optimal debulking surgery.
We preserved the left adnexa in one patient because she was 37
years old. In the other patient, we did not stage the tumor after left
salpingo-oophorectomy, which was performed in another hospital,
because the stage was presumed to be IA by the imaging study.
Instead, the patient received adjuvant chemotherapy. In our study,
six of the 10 patients underwent postoperative adjuvant chemo-
therapy because of advanced stage or incomplete staging operation.
All patients showed a complete response.
In a previous study, MBTs were reported to have a better
prognosis than other epithelial malignancies [15]. Most of our pa-
tients (60%) were diagnosed with a stage I tumor, and one patient
was diagnosed with a stage II tumor. However, four patients with
stage IIC or over experienced a recurrence during follow-up. Two
recurrent cases with pelvic metastasis showed favorable results
after intensive chemotherapy, regardless of the initial stage of the
tumor. The patient with the stage IIIC tumor is alive at 13 months
after recurrence on current chemotherapy. The patient with the
stage IV tumor showed no evidence of the disease > 12 years after
last chemotherapy. Lastly, two patients with distantmetastasis died
after showing a long-term survival of 49 months and 88 months,
respectively, after recurrence with intensive chemotherapy. These
outcomes are very encouraging, and they support the report byAustin and Norris [16] who described that the 5-year survival of
stage III/IV MBT is 0%.
So far, because of their rarity, only a few reports on MBTs are
available. This study is the second report including  10 cases
conducted in a single center following the study by Gezginç et al
[1]. The role of adjuvant chemotherapy inMBT is unclear because of
its rarity. However, our results showed that systemic chemotherapy
is beneﬁcial in patients with recurrence of a primary MBT of the
ovary, especially in the locoregional recurrence. A more compre-
hensive study including interventional trial is needed in the future
to better understand this disease.
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